Danaher (NYSE:DHR) Coverage Initiated by Analysts at DZ Bank

Equities research analysts at DZ Bank started coverage on shares of Danaher (NYSE:DHR) in a report released on Wednesday. The brokerage set a “buy” rating and a $210.00 price target on the conglomerate’s stock. DZ Bank’s price objective suggests a potential upside of 19.34% from the stock’s current price.

A number of other brokerages have also weighed in on DHR. Jefferies Financial Group restated a “buy” rating and issued a $245.00 price objective on shares of Danaher in a report on Tuesday, April 21st. Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Wolfe Research lowered Danaher from an “outperform” rating to a “peer perform” rating in a report on Monday. The Goldman Sachs Group decreased their price objective on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a report on Monday, April 13th. Finally, Morgan Stanley decreased their price objective on Danaher from $270.00 to $255.00 and set an “overweight” rating on the stock in a report on Wednesday, April 22nd. Twenty research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $235.14.

Danaher Price Performance

Danaher stock opened at $175.97 on Wednesday. The company’s fifty day moving average price is $181.91 and its 200 day moving average price is $207.20. Danaher has a 1 year low of $160.93 and a 1 year high of $242.80. The stock has a market capitalization of $124.54 billion, a P/E ratio of 34.04, a P/E/G ratio of 2.40 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.52 and a current ratio of 1.87.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, April 20th. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. The firm had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $6 billion. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The firm’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.88 EPS. As a group, equities research analysts anticipate that Danaher will post 8.43 earnings per share for the current fiscal year.

Institutional Trading of Danaher

Several institutional investors and hedge funds have recently bought and sold shares of DHR. State Street Corp grew its position in Danaher by 1.7% in the 4th quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock valued at $6,345,529,000 after acquiring an additional 472,608 shares in the last quarter. Capital International Investors grew its position in Danaher by 8.9% in the 4th quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock valued at $4,177,386,000 after acquiring an additional 1,487,768 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Danaher by 9.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate’s stock valued at $3,656,595,000 after acquiring an additional 1,334,221 shares in the last quarter. Wellington Management Group LLP grew its position in Danaher by 11.2% in the 4th quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock valued at $3,451,380,000 after acquiring an additional 1,517,904 shares in the last quarter. Finally, Norges Bank acquired a new position in Danaher in the 4th quarter valued at about $2,177,106,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.